The Danish infectious disease specialist has $340m (DKK 2.4m) lined up through orders for its MVA-BN vaccine known under the ...
The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only ...
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...
The two-day Oncology event will see industry experts from across the clinical trial space holding talks on subjects from AI ...
The FDA has released final draft recommendations for using real-world data and evidence in drug development.